Ensure pharmaceutical quality and safety by controlling organic and mutagenic impurities. Download this whitepaper to learn more.
本资源涵盖的关键主题
The pursuit of high-quality active substances remains paramount in the pharmaceutical industry. A critical factor in achieving this goal is meticulous control of impurity content. Evaluating impurities in pharmaceuticals is essential to guarantee both their safety and efficacy. These unintended molecules arise during synthesis, storage, or formulation, and some may harbor potential toxicity.
继续阅读
白皮书What do 230 FDA warning letters reveal about recurring sterile manufacturing deficiencies? This white paper analyses inspection findings from 2023–2025 and maps them to EU GMP Annex 1 expectations, revealing where manufacturers most frequently fall short of sustainable compliance.
阅读更多
白皮书Discover practical ways to streamline APR/PQR, reduce QA workload, and improve compliance through better data, templates, digital tools, and external support.
阅读更多
白皮书Learn how risk-based cleaning validation, HBELs, and modern analytical methods help ensure compliant, contamination-free pharmaceutical manufacturing. Download the whitepaper.
阅读更多